|
RPA3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.46350000293805E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.36099997938288E-09 |
| Normal-vs-Stage2 |
5.260500E-03 |
| Normal-vs-Stage3 |
1.213630E-04 |
| Normal-vs-Stage4 |
2.24829999950771E-07 |
| Stage1-vs-Stage2 |
2.275800E-01 |
| Stage1-vs-Stage3 |
5.013500E-02 |
| Stage1-vs-Stage4 |
3.519400E-01 |
| Stage2-vs-Stage3 |
9.475800E-01 |
| Stage2-vs-Stage4 |
1.117830E-01 |
| Stage3-vs-Stage4 |
4.123600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.96560000287738E-08 |
| Normal-vs-AfricanAmerican |
1.739240E-01 |
| Normal-vs-Asian |
1.69839997621324E-09 |
| Caucasian-vs-AfricanAmerican |
4.668300E-02 |
| Caucasian-vs-Asian |
7.084400E-02 |
| AfricanAmerican-vs-Asian |
1.733870E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.59040011663103E-10 |
| Normal-vs-Female |
1.28470000004821E-06 |
| Male-vs-Female |
6.782900E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.36739985790291E-10 |
| Normal-vs-Age(41-60Yrs) |
2.00790000000062E-05 |
| Normal-vs-Age(61-80Yrs) |
1.70601999999187E-05 |
| Normal-vs-Age(81-100Yrs) |
7.62229999999864E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.989700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.094800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.646600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.740400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.924800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.727000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.985200E-01 |
| Classical-VS-Follicular |
3.910400E-01 |
| Classical-VS-Other |
5.597200E-01 |
| Classical-VS-Normal |
6.88110000091058E-08 |
| Tall-VS-Follicular |
1.580950E-01 |
| Tall-VS-Other |
2.786200E-01 |
| Tall-VS-Normal |
9.373900E-04 |
| Follicular-VS-Other |
8.075600E-01 |
| Follicular-VS-Normal |
2.31519999949192E-07 |
| Other-VS-Normal |
4.116100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.13180000038682E-07 |
| Normal-vs-N1 |
1.92889999994783E-06 |
| N0-vs-N1 |
2.951600E-01 |
|
|
